Autolus Therapeutics (NASDAQ:AUTL) Reaches New 1-Year Low – Here’s Why

Autolus Therapeutics plc (NASDAQ:AUTL) shares hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $1.92 and last traded at $1.97, with a volume of 124566 shares changing hands. The stock had previously closed at $2.03.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on AUTL shares. Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target on the stock in a report on Friday, November 15th. The Goldman Sachs Group raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the company from $7.00 to $7.60 in a research note on Monday, November 18th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, January 13th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $10.40.

Autolus Therapeutics Price Performance

The business has a 50 day moving average of $2.37 and a 200 day moving average of $3.32. The firm has a market capitalization of $508.23 million, a price-to-earnings ratio of -1.58 and a beta of 2.02.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the prior year, the business posted ($0.26) earnings per share. As a group, equities analysts predict that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP lifted its stake in Autolus Therapeutics by 35.4% in the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after buying an additional 6,330,392 shares in the last quarter. FMR LLC raised its holdings in shares of Autolus Therapeutics by 44.6% during the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock worth $64,519,000 after acquiring an additional 5,478,706 shares during the period. Candriam S.C.A. acquired a new stake in shares of Autolus Therapeutics during the fourth quarter worth $7,500,000. JPMorgan Chase & Co. boosted its position in shares of Autolus Therapeutics by 145.3% during the third quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company’s stock worth $4,663,000 after buying an additional 761,008 shares during the period. Finally, Millennium Management LLC grew its holdings in shares of Autolus Therapeutics by 113.7% during the second quarter. Millennium Management LLC now owns 813,031 shares of the company’s stock worth $2,829,000 after buying an additional 432,503 shares in the last quarter. 72.83% of the stock is owned by institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.